Alta Fundamental Advisers LLC Acquires 75,000 Shares of Indivior PLC (NASDAQ:INDV)

Alta Fundamental Advisers LLC grew its holdings in Indivior PLC (NASDAQ:INDV - Free Report) by 23.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 400,000 shares of the company's stock after buying an additional 75,000 shares during the quarter. Indivior makes up 1.5% of Alta Fundamental Advisers LLC's portfolio, making the stock its 17th largest position. Alta Fundamental Advisers LLC owned 0.29% of Indivior worth $4,972,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in INDV. Claret Asset Management Corp acquired a new position in shares of Indivior during the fourth quarter worth approximately $9,304,000. CenterBook Partners LP raised its position in Indivior by 105.5% in the 4th quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock worth $14,268,000 after purchasing an additional 589,158 shares during the last quarter. Marshall Wace LLP raised its position in Indivior by 659.7% in the 4th quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock worth $6,299,000 after purchasing an additional 440,072 shares during the last quarter. Foursixthree Capital LP acquired a new position in Indivior during the 4th quarter worth $4,639,000. Finally, SIH Partners LLLP bought a new position in Indivior in the 4th quarter valued at $2,698,000. 60.33% of the stock is owned by institutional investors.

Indivior Stock Up 3.7 %

NASDAQ:INDV opened at $11.98 on Friday. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $18.59. The stock's fifty day simple moving average is $9.75 and its 200-day simple moving average is $10.44. The firm has a market capitalization of $1.65 billion, a P/E ratio of -34.23 and a beta of 0.93.

Indivior (NASDAQ:INDV - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.19. The firm had revenue of $266.00 million for the quarter, compared to analysts' expectations of $240.13 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. As a group, equities research analysts expect that Indivior PLC will post 1.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on INDV shares. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th. Piper Sandler cut their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th. Finally, Rodman & Renshaw assumed coverage on shares of Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 target price on the stock.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.